Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 2/6 |
1763 Stock Overview
China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China.
Rewards
Risk Analysis
No risks detected for 1763 from our risk checks.
China Isotope & Radiation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$17.70 |
52 Week High | HK$32.10 |
52 Week Low | HK$17.04 |
Beta | 0.82 |
1 Month Change | -8.67% |
3 Month Change | -19.55% |
1 Year Change | -44.34% |
3 Year Change | -3.91% |
5 Year Change | n/a |
Change since IPO | -11.94% |
Recent News & Updates
Is There Now An Opportunity In China Isotope & Radiation Corporation (HKG:1763)?
While China Isotope & Radiation Corporation ( HKG:1763 ) might not be the most widely known stock at the moment, it saw...
Shareholder Returns
1763 | HK Medical Equipment | HK Market | |
---|---|---|---|
7D | -2.2% | 15.3% | 2.1% |
1Y | -44.3% | -60.3% | -23.3% |
Return vs Industry: 1763 exceeded the Hong Kong Medical Equipment industry which returned -60.3% over the past year.
Return vs Market: 1763 underperformed the Hong Kong Market which returned -23.3% over the past year.
Price Volatility
1763 volatility | |
---|---|
1763 Average Weekly Movement | 5.4% |
Medical Equipment Industry Average Movement | 9.1% |
Market Average Movement | 7.0% |
10% most volatile stocks in HK Market | 13.8% |
10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 1763 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 1763's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1983 | 3,120 | n/a | https://www.circ.com.cn |
China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates through five segments: Pharmaceuticals; Radioactive Source Products; Irradiation; Radiation Therapy Equipment and Related Services; and Independent Clinical Medical and Laboratory Services, and Other Business. The Pharmaceuticals segment engages in the research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmaceuticals; UBT kits and analyzers; and in vitro immunoassay diagnostic reagents and kits.
China Isotope & Radiation Fundamentals Summary
1763 fundamental statistics | |
---|---|
Market Cap | CN¥4.83b |
Earnings (TTM) | CN¥335.75m |
Revenue (TTM) | CN¥5.14b |
14.4x
P/E Ratio0.9x
P/S RatioIs 1763 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1763 income statement (TTM) | |
---|---|
Revenue | CN¥5.14b |
Cost of Revenue | CN¥1.90b |
Gross Profit | CN¥3.24b |
Other Expenses | CN¥2.91b |
Earnings | CN¥335.75m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
Earnings per share (EPS) | 1.05 |
Gross Margin | 63.03% |
Net Profit Margin | 6.53% |
Debt/Equity Ratio | 12.6% |
How did 1763 perform over the long term?
See historical performance and comparisonDividends
2.5%
Current Dividend Yield36%
Payout RatioValuation
Is 1763 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1763?
Other financial metrics that can be useful for relative valuation.
What is 1763's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | CN¥4.83b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 0.9x |
Enterprise Value/EBITDA | 5.3x |
PEG Ratio | 1x |
Price to Earnings Ratio vs Peers
How does 1763's PE Ratio compare to its peers?
1763 PE Ratio vs Peers |
---|
Company | PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 142.4x |
Price-To-Earnings vs Peers: 1763 is good value based on its Price-To-Earnings Ratio (14.4x) compared to the peer average (142.4x).
Price to Earnings Ratio vs Industry
How does 1763's PE Ratio compare vs other companies in the Medical Equipment Industry?
Price-To-Earnings vs Industry: 1763 is good value based on its Price-To-Earnings Ratio (14.4x) compared to the Hong Kong Medical Equipment industry average (17.1x)
Price to Earnings Ratio vs Fair Ratio
What is 1763's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 14.4x |
Fair PE Ratio | 12.6x |
Price-To-Earnings vs Fair Ratio: 1763 is expensive based on its Price-To-Earnings Ratio (14.4x) compared to the estimated Fair Price-To-Earnings Ratio (12.6x).
Share Price vs Fair Value
What is the Fair Price of 1763 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 1763 (HK$17.7) is trading below our estimate of fair value (HK$26.59)
Significantly Below Fair Value: 1763 is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: 1763 is good value based on its PEG Ratio (1x)
Discover undervalued companies
Future Growth
How is China Isotope & Radiation forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
14.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1763's forecast earnings growth (14.5% per year) is above the savings rate (1.5%).
Earnings vs Market: 1763's earnings (14.5% per year) are forecast to grow slower than the Hong Kong market (17% per year).
High Growth Earnings: 1763's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1763's revenue (14.3% per year) is forecast to grow faster than the Hong Kong market (10.3% per year).
High Growth Revenue: 1763's revenue (14.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1763's Return on Equity is forecast to be low in 3 years time (10.3%).
Discover growth companies
Past Performance
How has China Isotope & Radiation performed over the past 5 years?
Past Performance Score
4/6Past Performance Score 4/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-1.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1763 has high quality earnings.
Growing Profit Margin: 1763's current net profit margins (6.5%) are higher than last year (5%).
Past Earnings Growth Analysis
Earnings Trend: 1763's earnings have declined by 1.9% per year over the past 5 years.
Accelerating Growth: 1763's earnings growth over the past year (57.2%) exceeds its 5-year average (-1.9% per year).
Earnings vs Industry: 1763 earnings growth over the past year (57.2%) exceeded the Medical Equipment industry 35.4%.
Return on Equity
High ROE: 1763's Return on Equity (11.2%) is considered low.
Discover strong past performing companies
Financial Health
How is China Isotope & Radiation's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: 1763's short term assets (CN¥6.7B) exceed its short term liabilities (CN¥4.0B).
Long Term Liabilities: 1763's short term assets (CN¥6.7B) exceed its long term liabilities (CN¥470.9M).
Debt to Equity History and Analysis
Debt Level: 1763 has more cash than its total debt.
Reducing Debt: 1763's debt to equity ratio has reduced from 32.5% to 12.6% over the past 5 years.
Debt Coverage: 1763's debt is well covered by operating cash flow (104.1%).
Interest Coverage: 1763's interest payments on its debt are well covered by EBIT (243.7x coverage).
Balance Sheet
Discover healthy companies
Dividend
What is China Isotope & Radiation current dividend yield, its reliability and sustainability?
Dividend Score
1/6Dividend Score 1/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
2.47%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 1763's dividend (2.47%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.74%).
High Dividend: 1763's dividend (2.47%) is low compared to the top 25% of dividend payers in the Hong Kong market (7.89%).
Stability and Growth of Payments
Stable Dividend: 1763 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 1763's dividend payments have increased, but the company has only paid a dividend for 4 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (36%), 1763's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (32.5%), 1763's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
2.5yrs
Average board tenure
CEO
China Isotope & Radiation has no CEO, or we have no data on them.
Board Members
Experienced Board: 1763's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
China Isotope & Radiation Corporation's employee growth, exchange listings and data sources
Key Information
- Name: China Isotope & Radiation Corporation
- Ticker: 1763
- Exchange: SEHK
- Founded: 1983
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: HK$5.662b
- Shares outstanding: 319.87m
- Website: https://www.circ.com.cn
Number of Employees
Location
- China Isotope & Radiation Corporation
- No. 66 Changwa Middle Street
- Haidian District
- Beijing
- China
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/06/26 00:00 |
End of Day Share Price | 2022/06/24 00:00 |
Earnings | 2021/12/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.